{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:06:11Z","timestamp":1791237971510,"version":"4.1.0"},"reference-count":58,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2022,7,3]]},"DOI":"10.1080\/14728214.2022.2110239","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T15:48:58Z","timestamp":1659714538000},"page":"241-261","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Emerging drugs for the treatment of acne: a review of phase 2 &amp; 3 trials"],"prefix":"10.1080","volume":"27","author":[{"given":"Siddharth","family":"Bhatt","sequence":"first","affiliation":[{"name":"Dermatology, Armed Forces Medical College, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kothari","sequence":"additional","affiliation":[{"name":"Dermatology, Command Hospital Air Force, Bengaluru, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durga Madhab","family":"Tripathy","sequence":"additional","affiliation":[{"name":"Dermatology, Military Hospital, Agra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunmeet","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Dermatology, 7 Air Force Hospital, Kanpur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Babaei","sequence":"additional","affiliation":[{"name":"Dermatology, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Goldust","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Medical Center Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"issue":"8","key":"cit0002","first-page":"CD002086","volume":"15","author":"Garner SE","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S234231"},{"key":"cit0004","volume-title":"Comprehensive dermatologic drug therapy. Fourth","author":"Wolverton SE","year":"2020"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadr.2021.100230"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.051"},{"issue":"3","key":"cit0007","first-page":"190","volume":"84","author":"Alvarez-S\u00e1nchez M","year":"2016","journal-title":"Cir Cir Engl Ed"},{"key":"cit0008","unstructured":"Acne Medication Market. Global Market Insights; 2020. Report No.: GMI3010."},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14172"},{"issue":"1","key":"cit0010","first-page":"16","volume":"47","author":"Montilla CLE","year":"2019","journal-title":"Med Cutan Iber Lat Am"},{"issue":"5","key":"cit0011","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4103\/ijd.IJD_557_18","volume":"66","author":"Bubna AK","year":"2021","journal-title":"Indian J Dermatol"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2019-0199"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.135492"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-020-00299-z"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0345-x"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2013.10.065"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.3390\/cosmetics7030070"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12469889"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13340"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16719"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0465"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.10.100"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.175927"},{"key":"cit0024","unstructured":"Nature scientific reports has published a peer reviewed paper showing important immune response benefits associated with aobiome\u2019s B244 ammonia oxidizing bacteria drug therapy [Internet]. [cited 2022 Mar 30]. Available from: https:\/\/www.prnewswire.com\/news-releases\/nature-scientific-reports-has-published-a-peer-reviewed-paper-showing-important-immune-response-benefits-associated-with-aobiomes-b244-ammonia-oxidizing-bacteria-drug-therapy-301334632.html"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93299-1"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64628"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.292"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1080\/19381980.2015.1063751"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.3945\/jn.109.119784"},{"key":"cit0030","unstructured":"Clinical Trials Register [Internet]. [cited 2022 Mar 30]. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-003307-19\/DE"},{"key":"cit0031","doi-asserted-by":"crossref","unstructured":"Picardo M, Cardinali C, La Placa M, et al. Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial. Br J Dermatol. 2022 Jun 23;bjd.21663.","DOI":"10.1111\/bjd.21663"},{"key":"cit0032","unstructured":"pharma letter [Internet]. [cited 2022 Mar 30]. Available from: https:\/\/www.thepharmaletter.com\/article\/ct-s-acne-drug-zyflo-fails-in-ph-ii-trial"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2017.08.007"},{"issue":"6","key":"cit0034","first-page":"634","volume":"20","author":"Del Rosso JQ","journal-title":"J Drugs Dermatol JDD"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020939926"},{"issue":"8","key":"cit0036","first-page":"12","volume":"9","author":"Baldwin H","year":"2016","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"2","key":"cit0037","first-page":"12","volume":"69","author":"Leyden JJ","year":"2002","journal-title":"Cutis"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1001\/jamafacial.2018.1404"},{"issue":"2","key":"cit0039","first-page":"92","volume":"70","author":"Saple DG","year":"2004","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"cit0040","unstructured":"Talarozole - adisinsight [Internet]. [cited 2022 Mar 30]. Available from: https:\/\/adisinsight.springer.com\/drugs\/800020802"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07896.x"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.053"},{"key":"cit0043","unstructured":"Dermira\u2019s two phase 3 trials evaluating olumacostat [internet]. [cited 2022 Mar 30]. Available from: https:\/\/www.globenewswire.com\/news-release\/2018\/03\/05\/1414799\/0\/en\/Dermira-s-Two-Phase-3-Trials-Evaluating-Olumacostat-Glasaretil-in-Patients-with-Acne-Vulgaris-Did-Not-Meet-Co-Primary-Endpoints.html"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.01.026"},{"key":"cit0045","unstructured":"Xenon Pharmaceuticals Announces XEN801 Did Not Meet [Internet]. [cited 2022 Mar 30]. Available from: https:\/\/www.globenewswire.com\/news-release\/2017\/03\/24\/943883\/0\/en\/Xenon-Pharmaceuticals-Announces-XEN801-Did-Not-Meet-Efficacy-Endpoints-in-Phase-2-Clinical-Trial-in-Patients-with-Moderate-to-Severe-Acne.html"},{"key":"cit0046","unstructured":"Ascletis announces first patient dosed in the phase ii clinical trial of fasn inhibitor asc40 for treatment of moderate to severe acne [Internet]. [cited 2022 Mar 30]. Available from: https:\/\/www.prnewswire.com\/news-releases\/ascletis-announces-first-patient-dosed-in-the-phase-ii-clinical-trial-of-fasn-inhibitor-asc40-for-treatment-of-moderate-to-severe-acne-301460288.html"},{"key":"cit0047","unstructured":"A study of a new drug treatment for acne - full text view - clinicalTrials.gov [Internet]. [cited 2022 Mar 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01326780"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.5414\/CP201861"},{"issue":"8","key":"cit0049","first-page":"737","volume":"7","author":"Ansarin H","year":"2008","journal-title":"J Drugs Dermatol JDD"},{"issue":"6","key":"cit0050","first-page":"560","volume":"14","author":"Carrasco D","year":"2015","journal-title":"J Drugs Dermatol JDD"},{"key":"cit0051","unstructured":"Efficacy and safety study of gevokizumab to treat moderate to severe acne vulgaris - full text view - clinicalTrials.gov [Internet]. [cited 2022 Mar 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01498874"},{"key":"cit0052","unstructured":"XOMA announces encouraging interim results from gevokizumab phase 2 study for moderate to severe acne vulgaris - aktuell - servier (suisse) S.A. coversum, Preterax, Fludex,Diamicron, Locabiotal,Arcalion, Daflon [Internet]. [cited 2022 Mar 30]. Available from: https:\/\/www.servier.ch\/de\/aktuell\/news-detail\/2\/xoma-announces-encouraging-interim-results-from-gevokizumab-phase-2-study-for-moderate-to-severe-acne-vulgaris\/"},{"key":"cit0053","unstructured":"AnaptysisBio Scraps Development of Imsidolimab for Acne After Disappointing Phase 2 Trial | 2022-03-15 | FDAnews [Internet]. [cited 2022 Mar 30]. Available from: https:\/\/www.fdanews.com\/articles\/206995-anaptysisbio-scraps-development-of-imsidolimab-for-acne-after-disappointing-phase-2-trial"},{"key":"cit0054","unstructured":"AOBiome Therapeutics Reports Positive Efficacy Results from Phase 2b Clinical trial of ammonia oxidizing bacteria (aob) for the treatment of acne vulgaris - aobiome [Internet]. [cited 2022 Mar 30]. Available from: https:\/\/www.aobiome.com\/pressreleases\/aobiome-therapeutics-reports-positive-efficacy-results-from-phase-2b-clinical-trial-of-ammonia-oxidizing-bacteria-aob-for-the-treatment-of-acne-vulgaris\/"},{"key":"cit0055","unstructured":"clinical trial in subjects with mild to moderate acne vulgaris - full text view - clinicalTrials.gov [Internet]. [cited 2022 Mar 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02832063"},{"issue":"11","key":"cit0056","first-page":"1228","volume":"9","author":"Geria AN","year":"2008","journal-title":"Curr Opin Invest Drugs Lond Engl 2000"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.93193"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00546-5"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2022.2110239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T21:00:40Z","timestamp":1727730040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2022.2110239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7,3]]}},"alternative-id":["10.1080\/14728214.2022.2110239"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2022.2110239","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}